Table 2.
Pathogens | All | Community-acquired IE | Healthcare-associated IE | ||
---|---|---|---|---|---|
N = 200 | non-IVDU n = 89 |
IVDU n = 59 |
non-nosocomial n = 30 |
nosocomial IE n = 22 |
|
Staphylococci, n (%) | 115 (57.5) | 21 (23.6) | 54 (91.5) | 23 (76.7) | 17 (77.3) |
MSSA | 65 | 15 | 42 | 8 | 0 |
MRSA | 44 | 2 | 12 | 13 | 17 |
Coagulase-negative Staphylococci | 6 | 4 | 0 | 2 | 0 |
Streptococci, n (%) | 57 (28.5) | 50 (56.2) | 1 (1.7) | 4 (13.3) | 2 (9.1) |
Viridans streptococci | 38 | 35 | 0 | 3 | 0 |
Streptococcus bovis | 9 | 8 | 0 | 1 | 0 |
Streptococcus agalactiae | 5 | 3 | 1 | 0 | 1 |
Streptococcus pyogenes | 1 | 1 | 0 | 0 | 0 |
Streptococcus pneumoniae | 1 | 1 | 0 | 0 | 0 |
NVS | 3 | 2 | 0 | 0 | 1 |
Enterococci, n (%) | 9 (4.5) | 5 (5.6) | 0 (0) | 3 (10.0) | 1 (4.5) |
Enterococcus faecalis | 8 | 5 | 0 | 2 | 1 |
Enterococcus faecium | 1 | 0 | 0 | 1 | 0 |
Gram negative bacilli, n (%) | 3 (1.5) | 0 (0) | 2 (3.4) | 0 (0) | 1 (4.5) |
Pseudomonas aeruginosa | 1 | 0 | 1 | 0 | 0 |
Chryseobacterium indologenes | 1 | 0 | 0 | 0 | 1 |
Enterobacter cloacae | 1 | 0 | 1 | 0 | 0 |
HACEK group, n (%) | 2 (1.0) | 2 (2.2) | 0 (0) | 0 (0) | 0 (0) |
Haemophilus actinomycetemcomitans | 1 | 1 | 0 | 0 | 0 |
Haemophilus parainfluenzae | 1 | 1 | 0 | 0 | 0 |
Others, n (%) | 6 (3.0) | 5 (5.6) | 1 (1.7) | 0 (0) | 0 (0) |
Rothia dentocariosa | 2 | 1 | 1 | 0 | 0 |
Finegoldia magna | 1 | 1 | 0 | 0 | 0 |
Lactococcus lactis | 1 | 1 | 0 | 0 | 0 |
Lactococcus gravieae | 1 | 1 | 0 | 0 | 0 |
Candida albicans | 1 | 1 | 0 | 0 | 0 |
Culture negative, n (%) | 8 (4.0) | 6 (6.7) | 1 (1.7) | 0 (0) | 1 (4.5) |
IE, infective endocarditis; IVDU, intravenous drug user; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; NVS, nutritionally variant streptococci; HACEK, Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella species